International Journal of Hematology

, Volume 98, Issue 3, pp 361–365

Nilotinib-induced interstitial lung disease

  • Se-Il Go
  • Won Sup Lee
  • Gyeong-Won Lee
  • Jung Hun Kang
  • Myung Hee Kang
  • Jeong-Hee Lee
  • Hoon-Gu Kim
Case Report

DOI: 10.1007/s12185-013-1398-5

Cite this article as:
Go, S., Lee, W.S., Lee, G. et al. Int J Hematol (2013) 98: 361. doi:10.1007/s12185-013-1398-5

Abstract

Nilotinib is a second-generation tyrosine kinase inhibitor active in patients with chronic myeloid leukemia (CML) resistant to imatinib, and has been recently approved for newly diagnosed patients. We present a case of nilotinib-induced interstitial lung disease (ILD). A 67-year-old female patient was initially treated with imatinib for chronic-phase Philadelphia chromosome-positive (Ph+) CML. Imatinib was replaced by nilotinib because of hematological toxicity. The patient had received nilotinib for about 3 years without significant adverse effects. She visited the clinic due to chronic cough; chest X-ray revealed consolidations in both lung fields. Nilotinib-induced ILD was diagnosed based on intensive workup, including lung biopsy. She responded dramatically to corticosteroid therapy. To our knowledge, this is the first reported case of nilotinib-induced ILD in a patient with Ph+ CML. We emphasize that if unexplained lung abnormalities progress in patients receiving nilotinib, physicians should consider this potentially fatal complication in their differential diagnoses.

Keywords

NilotinibChronic myeloid leukemiaInterstitial lung disease

Copyright information

© The Japanese Society of Hematology 2013

Authors and Affiliations

  • Se-Il Go
    • 1
  • Won Sup Lee
    • 1
  • Gyeong-Won Lee
    • 1
  • Jung Hun Kang
    • 1
  • Myung Hee Kang
    • 1
  • Jeong-Hee Lee
    • 2
  • Hoon-Gu Kim
    • 1
  1. 1.Division of Hematology-Oncology, Department of Internal Medicine, Gyeongnam Regional Cancer CenterInstitute of Health Sciences, Gyeongsang National University School of MedicineJinjuKorea
  2. 2.Department of Pathology, Institute of Health SciencesGyeongsang National University School of MedicineJinjuKorea